IQVIA(US:IQV)2026-02-05 15:00Financial Data and Key Metrics Changes - The company reported a full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% for 2025, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [4][24] - Fourth quarter revenue was $4,364 million, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted diluted EPS of $3.42, an increase of 9.6% year-over-year [20][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [21] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1,821 million, up 9.8% reported and 7.1% at constant currency [20] - R&D Solutions revenue for Q4 was $2,333 million, up 9.1% reported and 8.2% at constant currency [20] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, an increase of 18.6% reported and 15.3% at constant currency [20] Market Data and Key Metrics Changes - The backlog reached a new record of $32.7 billion at the end of Q4, growing 5.3% compared to the prior year [9][23] - Qualified pipeline was about 10% higher year-over-year, with double-digit growth in RFP flow across all segments [9] Company Strategy and Development Direction - The company is focusing on simplifying its organization into two reporting segments: Commercial Solutions and R&D Solutions, to better align with evolving market demands [14][15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [10] - The company is investing in AI-driven innovations and has deployed over 150 AI agents across various use cases [37][40] Management's Comments on Operating Environment and Future Outlook - Management noted that the macroeconomic environment led to slower customer decision-making but indicated that demand indicators became more favorable as the year progressed [4][5] - The company expects revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [25][26] Other Important Information - The company was recognized for its AI leadership, being ranked number one for generative AI leadership in life sciences by Everest Group [11] - The CFO, Ron Bruehlman, is transitioning to a senior advisory role after a long tenure [16][17] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is viewed as an opportunity rather than a challenge, emphasizing the company's proprietary data and domain expertise as key differentiators [31][32][40] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance the company's payer provider analytics capabilities, with Cedar Gate contributing approximately $140 million in revenue and $36-37 million in adjusted EBITDA for 2025 [46][47] Question: Impact of AI on trial efficiency and demand dynamics - Management stated that AI is expected to improve trial efficiency but does not foresee a reduction in the number of trials conducted by large pharma clients [68][70]